Cardinal Health to acquire Integrated Oncology Network for $1.12 billion
As part of the deal, ION practices will join Navista, Cardinal Health’s oncology practice alliance.
New Search
If you are not happy with the results below please do another search
Search
50 search results for:
Aligos claims mid-stage win in MASH, but investors are skeptical
/in Therapeutics/by BioSpaceAn unusual placebo effect in Aligos Therapeutics’ Phase IIa trial is driving shareholder skepticism for its metabolic dysfunction-associated steatohepatitis candidate, according to Jefferies analyst Michael Yee.
Senate bill seeks to spare small biotechs from IRA’s drug price negotiations
/in Business, Therapeutics/by BioSpaceWhile unlikely to pass this year, given the Democrats’ control over the White House and Senate, the proposed legislation might be a harbinger of the Republicans’ agenda next year for the Inflation Reduction Act should they win the November elections.
Sanofi’s tolebrutinib drug delays progressive MS by 31% in trial
/in R&D, Therapeutics/by Reuters HealthThe news comes as the French drugmaker is eyeing a request for approval later this year.
Daiichi Sankyo debuts Enhertu ad during Thursday Night Football
/in Marketing & Advertising, Therapeutics/by Maria FontanazzaThe company is going big with the primetime nationwide launch of its first DTC campaign in the oncology space.
After fed rate cut, biotech stocks face ‘anticlimactic’ reality
/in Business/by BioSpaceThe drop in interest rate is slightly bigger than anticipated and good news for the biotech industry, but little will change in the near term.
EU regulator backs use of Novo’s Wegovy for obesity-related heart condition
/in Therapeutics/by Reuters HealthThis marks the regulator’s second backing for a use of Wegovy beyond weight loss and further strengthens Novo’s case that the medicine has multiple health benefits.
AstraZeneca wins rare autoimmune indication for asthma biologic Fasenra
/in Therapeutics/by BioSpaceWith the FDA’s approval, Fasenra will compete with GSK’s Nucala, which in December 2017 became the first biologic approved for eosinophilic granulomatosis with polyangiitis.
4DMT’S gene therapy for AMD clears Phase II, heads to late-stage studies
/in R&D, Therapeutics/by BioSpace4D Molecular Therapeutics reported its experimental gene therapy demonstrated a nearly 90% reduction in the need for annualized standard-of-care injections in patients with wet age-related macular degeneration.
A second Zantac cancer trial ends with hung jury
/in Therapeutics/by Reuters HealthThe latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, as jurors in Chicago were unable to agree on whether Boehringer Ingelheim must pay damages to an Illinois man who said he developed prostate cancer as a result of taking the drug, according to the man’s lawyer.